Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DILT-CD vs AFEDITAB CR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Diltiazem inhibits calcium ion influx during depolarization of cardiac and vascular smooth muscle cells, thereby reducing intracellular calcium levels. It decreases sinoatrial and atrioventricular nodal conduction and dilates coronary and peripheral arteries.
Nifedipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.
Hypertension,Chronic stable angina,Variant angina,Atrial fibrillation or atrial flutter (rate control),Paroxysmal supraventricular tachycardia
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
180-360 mg PO once daily (extended-release); 300-540 mg PO once daily for hypertension; 120-480 mg PO once daily for angina; IV: 0.25 mg/kg bolus over 2 min, then 5-15 mg/hr continuous infusion.
30-60 mg orally once daily, extended-release; maximum 90 mg/day.
Terminal elimination half-life 7-10 hours; clinically relevant in hepatic impairment (prolonged to 14-20 hours) and in elderly
Terminal elimination half-life is 6-11 hours; prolonged in hepatic impairment and elderly due to reduced clearance
Hepatic via CYP3A4; undergoes deacetylation and N-demethylation.
Primarily hepatic via CYP3A4; undergoes extensive first-pass metabolism.
Renal 2-4% unchanged; extensive hepatic metabolism; 60-70% fecal, 30-40% renal as metabolites
Renal (80% as inactive metabolites), fecal (15% as metabolites), unchanged drug (<1%)
85-90% bound to plasma proteins (primarily albumin and alpha-1-acid glycoprotein)
92-98% bound to plasma proteins (primarily albumin)
3-5 L/kg; large Vd indicates extensive tissue binding, with highest concentrations in liver, lung, and spleen
0.5-0.9 L/kg; high distribution indicates extensive tissue binding
Oral immediate-release: 40-60% (first-pass effect); oral sustained-release: 30-50%; IV: 100%
Oral extended-release: approximately 50-60% due to first-pass metabolism; absolute bioavailability is 45-60%
No dosage adjustment required for mild-moderate renal impairment; use caution and consider dose reduction in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation.
No adjustment required for any degree of renal impairment, but use with caution in patients with severe renal failure due to risk of hypotension.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25-50%; Child-Pugh C: contraindicated or use with extreme caution, reduce dose by at least 50%.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Not FDA-approved for pediatric use; off-label dosing for hypertension: extended-release initial 2.5-5 mg/kg/day PO once daily, max 10 mg/kg/day up to 360 mg daily; for supraventricular tachycardia: IV bolus 0.1-0.3 mg/kg over 2 min, may repeat after 30 min, max 10 mg/dose.
Not recommended for use in pediatric patients; safety and efficacy not established.
Start at lower end of dosing range (e.g., 120 mg PO once daily for hypertension); titrate slowly; monitor for hypotension, bradycardia, and constipation; consider reduced initial dose due to altered pharmacokinetics.
Initiate at lower end of dosing range (30 mg once daily) due to increased sensitivity to hypotensive effects and potential for reduced hepatic clearance.
None.
No FDA black box warning.
May cause bradycardia, heart block, or heart failure exacerbation,Use caution in patients with impaired left ventricular function,May cause hypotension, especially in patients with aortic stenosis,May increase digoxin and cyclosporine levels,Abrupt withdrawal may exacerbate angina,Hepatic impairment may require dose adjustment,Avoid use in patients with sick sinus syndrome or second/third-degree AV block without pacemaker
Hypotension, especially with immediate-release formulations,Peripheral edema,Hepatic impairment,Increased angina/acute MI upon withdrawal or dose escalation,Beta-blocker withdrawal,Congestive heart failure
Sick sinus syndrome (except with functioning pacemaker),Second- or third-degree AV block (except with pacemaker),Hypotension (systolic <90 mm Hg),Acute myocardial infarction with pulmonary congestion,Known hypersensitivity to diltiazem,Concomitant use with dantrolene (risk of ventricular fibrillation),Concurrent use with ivabradine
Hypersensitivity to nifedipine or any component,Cardiogenic shock,Concomitant use with strong CYP3A4 inducers (e.g., rifampin),Kock pouch (ileostomy)
Avoid grapefruit and grapefruit juice; they inhibit CYP3A4 and increase diltiazem levels, raising risk of toxicity. High-fat meals may increase absorption; take with food to reduce gastrointestinal upset. Alcohol may enhance hypotension and dizziness; limit consumption.
Grapefruit juice increases nifedipine levels via CYP3A4 inhibition; avoid consumption. High-fat meals may delay absorption but do not alter overall exposure. Avoid alcohol as it can exacerbate vasodilation and hypotension.
DILT-CD is a formulation of diltiazem, a calcium channel blocker. In animal studies, diltiazem has been associated with fetal skeletal abnormalities and reduced fetal weight at high doses. Human data are limited; however, diltiazem is generally avoided in the first trimester due to potential teratogenic effects. In the second and third trimesters, use is cautioned due to risks of maternal hypotension and possible fetal hypoxia. Diltiazem crosses the placenta and may cause fetal bradycardia.
Teratogenic effects not established; first trimester: no data in humans, animal studies show no teratogenicity; second and third trimesters: risk of fetal hypoxia, intrauterine growth restriction (IUGR), and oligohydramnios; may cause neonatal hypotension, bradycardia, and hypoglycemia if used near term. Contraindicated in pregnancy for hypertension; use only if benefit outweighs risk (e.g., tocolysis).
Diltiazem is excreted into breast milk in small amounts; the estimated infant dose is approximately 1% of the maternal weight-adjusted dose. The milk-to-plasma ratio (M/P) is reported as 0.5-1.0. Caution is advised due to potential cardiovascular effects in the nursing infant, though limited data suggest low risk. Monitor infant for bradycardia and hypotension.
Nifedipine excreted into breast milk; M/P ratio approximately 0.42-0.77; limited human data; no adverse effects reported in infants; use with caution during breastfeeding.
Pregnancy may increase diltiazem clearance due to expanded plasma volume and enhanced hepatic metabolism. Dose adjustments may be needed to maintain efficacy; however, specific pharmacokinetic studies for DILT-CD are lacking. Generally, use the lowest effective dose and monitor clinical response. Titrate based on maternal blood pressure and heart rate.
Plasma clearance may increase due to higher volume of distribution and metabolism; no specific dose adjustment recommended; titrate based on maternal blood pressure and response; avoid around labor due to tocolytic effect.
DILT-CD is a calcium channel blocker (non-dihydropyridine) used for hypertension and angina. It has negative chronotropic and dromotropic effects; avoid in patients with sick sinus syndrome or second/third-degree AV block without a pacemaker. Monitor heart rate and PR interval. May increase digoxin levels; co-administration requires dose adjustment. Contraindicated with IV beta-blockers due to risk of bradycardia and heart failure.
AFEDITAB CR is a controlled-release formulation of nifedipine, a dihydropyridine calcium channel blocker. Avoid grapefruit juice as it inhibits CYP3A4 metabolism, increasing nifedipine levels. Use cautiously in patients with aortic stenosis or left ventricular dysfunction due to risk of hypotension. Do not crush or chew tablets; intact shell may appear in stool.
Take exactly as prescribed; do not crush or chew extended-release capsules.,May cause dizziness or lightheadedness; avoid driving until you know how this medication affects you.,Report slow heartbeat, shortness of breath, or swelling in your ankles or feet.,Limit alcohol intake as it may increase side effects.,Avoid grapefruit and grapefruit juice as they can increase drug levels and side effects.
Swallow the tablet whole; do not crush, chew, or break it.,Avoid grapefruit juice while taking this medication.,Do not discontinue abruptly; taper under medical supervision.,Report symptoms of hypotension like dizziness or fainting.,Limit alcohol intake as it may worsen side effects.,Monitor for fluid retention (ankle swelling) and notify doctor if worsening.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DILT-CD vs AFEDITAB CR, answered by our medical review team.
DILT-CD is a Calcium Channel Blocker that works by Diltiazem inhibits calcium ion influx during depolarization of cardiac and vascular smooth muscle cells, thereby reducing intracellular calcium levels. It decreases sinoatrial and atrioventricular nodal conduction and dilates coronary and peripheral arteries.. AFEDITAB CR is a Calcium Channel Blocker that works by Nifedipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DILT-CD and AFEDITAB CR depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DILT-CD is: 180-360 mg PO once daily (extended-release); 300-540 mg PO once daily for hypertension; 120-480 mg PO once daily for angina; IV: 0.25 mg/kg bolus over 2 min, then 5-15 mg/hr continuous infusion.. The standard adult dose of AFEDITAB CR is: 30-60 mg orally once daily, extended-release; maximum 90 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DILT-CD and AFEDITAB CR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DILT-CD is classified as Category C. DILT-CD is a formulation of diltiazem, a calcium channel blocker. In animal studies, diltiazem has been associated with fetal skeletal abnormalities and reduced fetal weight at hig. AFEDITAB CR is classified as Category C. Teratogenic effects not established; first trimester: no data in humans, animal studies show no teratogenicity; second and third trimesters: risk of fetal hypoxia, intrauterine gro. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.